Cidara Therapeutics Current Ratio 2014-2021 | CDTX
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
Cidara Therapeutics current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Cidara Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2021-06-30 |
$0.06B |
$0.03B |
1.80 |
| 2021-03-31 |
$0.05B |
$0.04B |
1.28 |
| 2020-12-31 |
$0.06B |
$0.04B |
1.48 |
| 2020-09-30 |
$0.06B |
$0.03B |
1.78 |
| 2020-06-30 |
$0.07B |
$0.03B |
2.22 |
| 2020-03-31 |
$0.08B |
$0.03B |
2.72 |
| 2019-12-31 |
$0.07B |
$0.03B |
2.18 |
| 2019-09-30 |
$0.08B |
$0.03B |
2.45 |
| 2019-06-30 |
$0.05B |
$0.02B |
2.57 |
| 2019-03-31 |
$0.06B |
$0.02B |
3.19 |
| 2018-12-31 |
$0.08B |
$0.02B |
3.88 |
| 2018-09-30 |
$0.09B |
$0.01B |
6.78 |
| 2018-06-30 |
$0.11B |
$0.02B |
7.11 |
| 2018-03-31 |
$0.07B |
$0.01B |
5.99 |
| 2017-12-31 |
$0.08B |
$0.01B |
6.43 |
| 2017-09-30 |
$0.07B |
$0.01B |
7.68 |
| 2017-06-30 |
$0.08B |
$0.01B |
7.49 |
| 2017-03-31 |
$0.09B |
$0.01B |
13.26 |
| 2016-12-31 |
$0.11B |
$0.01B |
11.83 |
| 2016-09-30 |
$0.08B |
$0.01B |
9.79 |
| 2016-06-30 |
$0.09B |
$0.01B |
17.22 |
| 2016-03-31 |
$0.10B |
$0.00B |
24.04 |
| 2015-12-31 |
$0.11B |
$0.01B |
18.12 |
| 2015-09-30 |
$0.12B |
$0.00B |
26.99 |
| 2015-06-30 |
$0.12B |
$0.00B |
40.11 |
| 2015-03-31 |
$0.06B |
$0.00B |
15.33 |
| 2014-12-31 |
$0.02B |
$0.00B |
7.16 |
| 2014-09-30 |
$0.00B |
|
0.00 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
$0.00B |
1.73 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.077B |
$0.012B |
|
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|
